{"schema_version":"secwatch.filing_event.v1","accession":"0001404644-26-000003","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.999497+00:00","generated_at":"2026-05-16T10:49:16.600652+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Neurogene doses multiple participants in Embolden Rett trial; interim data mid-2026","bullets":["Dosed multiple participants in Embolden registrational trial in Q4 2025; expect to complete dosing Q2 2026.","Plan to present interim Phase 1/2 data (8 pediatric, 2 adolescent/adult) with >=12-month follow-up mid-2026.","Cash runway through Q1 2028; early commercial-readiness activities underway including payor research.","Initiated 13 U.S. clinical trial sites; presenting at J.P. Morgan Healthcare Conference on Jan 14, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001404644-26-000003","json":"https://secwatch.observer/filing/0001404644-26-000003.json","markdown":"https://secwatch.observer/filing/0001404644-26-000003.md","text":"https://secwatch.observer/filing/0001404644-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000003/0001404644-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000003/ngne-20250811_d2.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:49:16.600652+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}